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Abstract We have developed a method for producing sterically
stabilized immunoliposomal drugs (SIL) readily applicable to a
‘mix and match’ combinatorial approach for the simple
manufacture of a variety of ligand-targeted liposomal drugs.
Ligands coupled to the terminus of polyethylene glycol (PEG) in
micelles formed from PEG-lipid derivatives (mPEG2000-DSPE)
could be transferred into preformed, drug-containing liposomes
from the micelles in a temperature- and time-dependent manner.
Antibody densities up to 100 Wg antibody/Wmol of phospholipid,
and up to 3 mol% of mPEG2000-DSPE, could be simultaneously
transferred from the ligand-coupled micelles into the liposomal
outer monolayer with negligible drug leakage from liposomes
during transfer and good stability in human plasma. Transfer of
anti-CD19 into SIL resulted in a three-fold increase in binding of
these liposomes to CD19+ human B cell lymphoma cells.
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1. Introduction
Liposomes are receiving widespread acceptance as carriers
of therapeutic drugs. Insertion of polyethylene glycol (PEG)-
derivatized phospholipids (PL) into liposomal membranes,
forming sterically stabilized liposomes (SL), decreases lipo-
some clearance and increases liposome accumulation in dis-
ease sites [1^3], which can result in increased therapeutic in-
dices for the entrapped drug (for reviews see [4^6]). Further
increases in selectivity of liposomal drugs can be achieved
through the use of targeting moieties attached at the liposome
surface, and several investigators have devised methods for
covalently attaching targeting molecules such as antibodies
(Abs) to the terminus of polymer-derivatized PL (reviewed
in [5,7^9]). If sterically stabilized targeted liposomes (SIL)
are to be useful in the clinic, ways of tailoring the SIL to
the patient’s disease pro¢le are needed that do not require a
separate manufacturing line for each ligand and drug combi-
nation. We therefore borrowed from combinatorial chemistry
to develop an approach which allows a variety of SIL to be
made by a simple mixing procedure from a small number of
starting products (Fig. 1).
Our aim was to develop a simple protocol to produce SIL
by transferring ligand-coupled PEG-lipid derivatives into pre-
formed liposomes from a micelle phase. These experiments are
an extension of our previous work in which we demonstrated
that mPEG2000, covalently linked to distearoylphosphatidyl-
ethanolamine (mPEG2000-DSPE), could be transferred from
a micellar phase into preformed classical liposomes (CL)
transforming them into SL [10]. Maleimide-terminated
PEG2000-DSPE (MAL-PEG2000-DSPE) is a coupling lipid,
which has previously been used to directly couple ligands to
the PEG terminus of SL, converting them into SIL [11]. It can
also be incorporated into PEG micelles, allowing coupling of
ligands to the micellar lipids, which could then, in theory, be
transferred into preformed liposomes, forming SIL.
The functionality of this approach was tested by transfer-
ring anti-CD19 PEG2000-DSPE into preformed SL and exam-
ining the binding of the resulting SIL to CD19 human B
lymphoma cells. In our previous work, treatment of murine
models of human B lymphoma with CD19-targeted SIL con-
taining entrapped DXR resulted in signi¢cantly increased life
spans of the animals compared to non-targeted liposomal
DXR or free drug [12]. A long-term aim is to reproduce these
results using the micelle transfer method for formation of SIL
described in this paper.
Liposome DXR, sterically stabilized with mPEG2000-DSPE
(Caelyx/Doxil), is currently approved for clinical use in the
treatment of refractory Kaposi’s sarcoma and ovarian cancer
[13^15]. It would be useful, from a manufacturing point of
view, if products such as this could be simply transformed
into patient-selective immunoliposomes in order to increase
their therapeutic index in the treatment of solid tumors or
hematological malignancies. For the micelle transfer method
of forming SIL to be clinically useful, it is important that the
process of transfer of mPEG2000-DSPE and ligand-PEG2000-
DSPE into preformed drug-containing liposomes not result in
premature release of the drug. As a test of this, we examined
the rate of release of entrapped DXR from preformed lipo-
somes when they were exposed to IgG-PEG2000-DSPE mi-
celles. We further tested the ability of ligand-PEG2000-DSPE
to transfer into SL, i.e. into liposomes which already had
mPEG2000-DSPE incorporated symmetrically into liposomal
membranes during their manufacture. In this regard, we meas-
ured the ability of IgG-PEG2000-DSPE micelles to transfer
both PEG and IgG into Caelyx/Doxil.
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2. Materials and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC), mPEG2000-DSPE
and sterically stabilized liposomes containing entrapped doxorubicin
(DXR-SL, Caelyx/Doxil) were generous gifts from SEQUUS Pharma-
ceuticals, Inc. (Menlo Park, CA, USA). MAL-PEG2000-DSPE was
custom synthesized by Shearwater Polymers, Inc. (AL, USA). Choles-
terol (CHOL) was purchased from Avanti Polar Lipids (AL, USA).
Sephadex G-50 and Sepharose CL-4B were purchased from Pharma-
cia Biotech (Uppsala, Sweden). Cholesteryl-[1,2-[3H](N)]-hexadecyl
ether (3H-CHE) and Na125I were purchased from Mandel Scienti¢c
(Ontario, Canada). [Carbamoyl-14C]mPEG2000-DSPE (14C-mPEG2000-
DSPE) was custom synthesized by Chemsyn Science Laboratories
(KS, USA). 2-Iminothiolane, metrizamide and sheep IgG (reagent
grade) were purchased from Sigma (MO, USA). Murine mAb anti-
CD19 was prepared by us from the FMC-63 murine CD19 hybridoma
cell line obtained from Dr. H. Zola (Children’s Health Research In-
stitute, Australia). Iodination of IgG was performed according to the
method described elsewhere [12]. The human B cell lymphoma line
Namalwa (ATCC CRL 1432) was obtained from American Type
Culture Collection (MD, USA). All other chemicals were of analytical
grade and purity.
2.2. Preparation of liposomes
Liposomes were prepared as previously described [11]. CL were
composed of HSPC:CHOL (2:1, molar ratio). SL additionally con-
tained 2 or 4 mol% mPEG2000-DSPE as a ratio to total PL (SL:2
mol% and SL:4 mol%). Caelyx/Doxil is HSPC:CHOL:mPEG2000-
DSPE, 2:1:0.184. Liposomes, including Caelyx/Doxil, had diameters
in the range of 90^100 nm. 3H-CHE was added as a non-metabolized
and non-exchangeable lipid tracer in some experiments [16]. When
applicable, DXR-loaded liposomes were prepared by remote loading
using ammonium sulfate gradients at a DXR:PL ratio of 0.2:1 (w/w),
as previously described [17]. The concentration of the liposome-en-
trapped DXR was determined by spectrophotometry (V= 490 nm),
and PL concentrations were determined using the Fiske-Sabbarow
colorimetric assay [18].
2.3. Preparation of IgG-coupled PEG2000-DSPE micelles
Sheep IgG or anti-CD19 mAb was coupled to micelles containing
mPEG2000-DSPE and the coupling lipid MAL-PEG2000-DSPE at a 4:1
molar ratio with trace amounts of 14C-mPEG2000-DSPE. mPEG2000-
DSPE was necessary to prevent intermicellar crosslinking during cou-
pling with IgG. Dried lipid ¢lm containing mPEG2000-DSPE and
MAL-PEG2000-DSPE were hydrated in HEPES bu¡er (pH 7.4) at a
concentration above the critical micellar concentration (CMC) of the
lipids with gentle agitation and heating at 60‡C. Coupling of IgG to
MAL-PEG2000-DSPE in the preformed micelles was carried out ac-
cording to a previously described method [11].
2.4. Transfer of IgG-PEG2000-DSPE into preformed liposomes
Transfer of IgG-PEG2000-DSPE into preformed liposomes was ini-
tiated by mixing aliquots of the IgG-micelles with preformed lipo-
somes for varying times and temperatures at various ratios of lip-
osomal PL to PEG2000-DSPE followed by chromatography on a
Sepharose CL-4B columns eluted with HEPES bu¡er (pH 7.4). The
amounts of transferred IgG, transferred PEG2000-DSPE and liposo-
mal PL in the liposome fractions were assayed. The size of resulting
liposomes was also determined.
2.5. Cell binding experiments
SIL[anti-CD19] for cell binding experiments were prepared by
transferring, at 60‡C for 1 h, anti-CD19 mAb-PEG2000-DSPE micellar
lipid into preformed SL:4 mol% at a liposomal PL:micellar PEG2000-
DSPE molar ratio of 100:3. SL were radiolabelled with 3H-CHE.
Namalwa cells (human B lymphoma cells) were plated at 1U106
cells/300 Wl RPMI 1640 supplemented with 10% (v/v) FBS in 24-
well tissue culture plates. SL:4 mol%, with or without transferred
anti-CD19 PEG2000-DSPE, were added to each well (200^800 nmol/
ml in a total volume of 600 Wl) and incubated at 37‡C in a humidi¢ed
atmosphere containing 5% CO2 in air. After 1 h incubation, the cells
were washed three times with cold PBS (pH 7.4), and the amount of
3H-CHE-liposomes associated with the cells was determined by scin-
tillation counting (Aqueous Scintillant scintillation £uid) in a Beck-
man LS-6800 counter. The amount of liposomes bound (in pmol PL)
was calculated from the initial speci¢c activity of 3H-CHE-liposomes.
2.6. In vitro doxorubicin leakage experiments
Liposomes containing entrapped DXR were chromatographed on a
Sephadex G-50 column immediately prior to use to remove any re-
sidual free DXR. IgG-coupled micelles were added to DXR-contain-
ing liposomes (1.5 mM) at a PL molar ratio of 3:100 and incubated at
either 37‡C or 60‡C. Liposomes contained DXR at concentrations
su⁄cient to cause £uorescence quenching and DXR leakage was de-
termined by £uorescence dequenching on a CytoFluor 2350 £uorim-
eter (Millipore, Bedford, MA, USA) at excitation and emission wave-
lengths of 485 nm and 590 nm, respectively. Total DXR (100%
dequenched) was measured by lysing the liposomes with 5% (v/v)
Triton X-100.
2.7. Dissociation of IgG-PEG2000-DSPE and mPEG2000-DSPE from
SIL in vitro
SIL were prepared by transferring IgG from micelles into SL:4
mol% (1.2 mM) followed by incubation in human plasma (50% v/v)
at 37‡C for 48 h. IgG-PEG2000-DSPE or mPEG2000-DSPE dissociated
from the SIL was determined by chromatography on a Sepharose
CL-4B columns in HEPES bu¡er, pH 7.4.
2.8. Statistics
Statistic analyses were performed using StatView software (Abacus
Concepts, Inc., CA, USA).
3. Results and discussion
The CMC of mPEG2000-DSPE and MAL-PEG2000-DSPE
was determined by monitoring micelle turbidity at 240 nm.
Regression analysis indicated that the CMCs for mPEG2000-
DSPE and MAL-PEG2000-DSPE were approximately 6.3 and
2.3 WM, respectively (not shown). Kanda et al. have previ-
ously demonstrated that a nitroxide spin-labeled diacyl gan-
glioside, which has a similar CMC, could be inserted from the
micelle phase into preformed multilamellar vesicles [19]. Mi-
celles composed of mPEG2000-DSPE and MAL-PEG2000-
DSPE (4:1, mol/mol) had a diameter of 30^50 nm. Following
coupling with IgG, the micelle diameter increased to approx-
imately 65^80 nm.
Coupling e⁄ciencies of IgG to preformed micelles were
determined by separating IgG-micelles from free IgG by ultra-
centrifugation on a metrizamide gradient. Free IgG was lo-
cated at the bottom of the gradient (Fig. 2). The main peak of
IgG-micelles (86%) was located at the middle of the gradient,
Fig. 1. Cartoon depicting the combinatorial approach to the forma-
tion of ligand-targeted liposomal anticancer drugs.
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similar to the peak for the micelles. This shows that most of
the IgG coupled to the preformed micelles.
It has been shown that symmetrical inclusion of 3^10 mol%
mPEG2000-DSPE (approximately 1.8^6 mol% PEG in the out-
er monolayer) in liposomes resulted in prolonged liposome
circulation times [20]. Above Ab densities of approximately
75 Wg/Wmol PL, an increased rate of clearance of SIL from
circulation has been reported [21]. Therefore, we aimed to
achieve approximately 3 mol% of mPEG2000-DSPE in the out-
er monolayer and an Ab density of less than 75 Wg/Wmol PL
following transfer of IgG-PEG2000-DSPE and mPEG2000-
DSPE into preformed liposomes. mPEG2000 already included
in the preformed liposomes might be expected to reduce the
transfer of additional IgG-PEG2000-DSPE and mPEG2000-
DSPE to the liposomes. To address this, transfer from IgG-
micelle conjugates into liposomes was examined for liposomes
containing 0, 2, 4 or 9.2 mol% of mPEG (Fig. 3). Transfer
experiments were carried out at 60‡C for 1 h which is above
the phase transition for HSPC [10]. The amount of IgG (Fig.
3A) and mPEG2000-DSPE (Fig. 3B) transferred to the lipo-
somes increased in proportion to the concentration of IgG-
coupled micelles added. In the presence of mPEG2000-DSPE,
the transfer of IgG-PEG2000-DSPE and mPEG2000-DSPE to
liposomes signi¢cantly decreased (Fig. 3A,B). Therefore, if the
liposomes already contain mPEG2000-DSPE, the additional
insertion of micellar IgG-PEG2000-DSPE into the liposomes
was inhibited. However, except at the highest concentration
of mPEG2000-DSPE, found in Caelyx/Doxil, su⁄cient transfer
of IgG into the preformed liposomes occurred that the result-
ing SIL should show good target binding as well as long
circulation times in vivo (Fig. 3A). For Caelyx/Doxil, the
presence of mPEG2000-DSPE in the outer monolayer (approx-
imately 5 mol%) allowed only low levels of insertion of IgG-
PEG2000-DSPE from micelles, which would be borderline for
targeting applications. The upper limit for introducing
mPEG2000-DSPE into bilayers appears to be approximately
6 mol% [10], consistent with our present ¢ndings. Zalipsky
et al. have also shown that 2 mol% of sialyl Lewisx oligosac-
charide-PEG2000-DSPE conjugate transferred into preformed
SL already containing 2.8 mol% outer monolayer PEG2000-
DSPE, resulting in 5.3 mol% PEG2000-DSPE incorporated
into outer monolayer following transfer [22].
It cannot be determined if there is net transfer of ligand
and/or mPEG2000-DSPE into the liposomes at high concen-
trations of pre-existing PEG2000-DSPE in the liposomal mem-
brane, of if there is a component of exchange/transfer with
some of the existing PEG2000-DSPE leaving the liposomes to
allow for the insertion of new PEG2000-DSPE or ligand-
PEG2000-DSPE-conjugates.
We determined changes in mean liposome diameter follow-
ing transfer of IgG-PEG2000-DSPE into liposomes, to ensure
that the product was within an acceptable diameter for ex-
travasation into diseased tissues, generally accepted as 150 nm
in diameter or less. Larger liposomes are rapidly removed
from the circulation into tissues of macrophage origin and
do not achieve signi¢cant levels in other tissues of the body
(reviewed in [23]). The mean diameters of the 100 nm CL and
SL increased by 32^36 nm and 22^26 nm, respectively. The
extension length of the grafted PEG on the surface of phos-
phatidylcholine liposomes containing 6 mol% mPEG2000-
DSPE is 6 nm [24]. The maximal linear dimension of IgG is
about 10.5 nm in the electron microscope by shadowing and
Fig. 2. Fractionation of IgG-micelles on a metrizamide gradient.
IgG-micelles containing 125I-labeled IgG and 14C-labeled mPEG2000-
DSPE were fractionated on a 40/50/60% (3/4/3 ml) discontinuous
metrizamide gradient at 37 000 rpm for 14 h in a SW41 rotor using
an L8-70 Ultracentrifuge (Beckman, CA, USA). Free IgG spiked
with tracer 125I-IgG and was also fractionated, for a control. Ten
1 ml fractions were collected starting from the bottom of the gra-
dient and counted for 125I and 14C. 125I counts from IgG-PEG2000-
DSPE micelles (b) ; 14C counts from IgG-PEG2000-DSPE micelles
(R) ; 125I counts from free IgG (a).
Fig. 3. Transfer of IgG-PEG2000-DSPE into preformed liposomes.
Transfer of IgG-PEG2000-DSPE into liposomes (HSPC:CHOL, 2:1
molar ratio, 100 nm in diameter, þ mPEG2000-DSPE) was initiated
by mixing aliquots of IgG-micelles with the liposomes at speci¢ed
ratios of liposomal PL to micellar PEG2000-DSPE at 60‡C for 1 h.
A: Transferred IgG. B: Transferred PEG2000-DSPE. CL (b,a) ;
SL:2 mol% (R,O) ; SL:4 mol% (F,E) ; Caelyx/Doxil (8,7). Data
are given as mean þ S.D. (n = 3).
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by negative contrast [25]. Therefore, our direct measurement
was consistent with the 33 and 21 nm estimate inferred from
these reports.
Time and temperature dependence of the transfer of lipid
from 55 Wg IgG-micelles into 1 Wmol HSPC:CHOL liposomes
was determined. At 37‡C, after 1 h incubation small amounts
of IgG-PEG2000-DSPE (10.4%) transferred to the liposomes.
After 24 h incubation the amount increased by approximately
four-fold to 45.1%, approximately one-half of the amount
transferred at 60‡C for 1 h. The ine⁄cient transfer might be
because the transfer was done below the Tc of HSPC (58‡C)
[10]. As seen for incubations at 60‡C (Fig. 3) the amount of
transfer at 37‡C was reduced in the present of pre-existing
mPEG2000-DSPE in the bilayers (not shown). In order to de-
termine if IgG-PEG2000-DSPE, not free IgG, was transferred
into the liposomes, the non-speci¢c adsorption of free IgG on
liposomes was also examined under similar incubation times
and temperatures. Less than 4% free IgG associated with lip-
osomes (P6 0.05 compared to IgG-PEG2000-DSPE for 1 h at
37‡C). This ¢nding suggests that the lipid anchor of polymer-
derivatized lipid (DSPE) coupled to IgG is responsible for the
transfer of IgG into the preformed liposomal membrane.
Dissociation and/or exchange of the ligand-PEG2000-DSPE
and/or mPEG2000-DSPE from the SIL would result in loss of
their ability to bind to their target cells and would increase
their clearance in vivo. To address this, we determined the o¡-
rate of IgG-PEG2000-DSPE and mPEG2000-DSPE from SIL
(60 Wg IgG/Wmol PL) after incubation in human plasma.
Even after a 48 h incubation, the transferred IgG and
mPEG2000-DSPE remained associated with the SIL
(102.3 þ 2.4% and 99.4 þ 8.2%, respectively). Parr et al. have
reported that a primary factor for retention of the PEG coat-
ing is the lipid anchor and DSPE is one of the better lipid
anchors [26]. The in vitro half-life of the exchange rate of
mPEG1900-DSPE out of the bilayer is reported to be 70 h at
37‡C [27]. However, the rate at which IgG-lipid derivatives or
mPEG2000-DSPE dissociate from the liposomes under in vivo
conditions has not yet been adequately addressed. Recent ex-
perience in our laboratory with anti-CD19 mAb attached to
the PEG terminus of liposomes by hydrazide or maleimide
linkages suggests that the in vivo stability of these immuno-
liposomes is good [12].
Addition of IgG-PEG2000-DSPE to the outer monolayer of
liposomes may cause transient membrane defects resulting in
some release of liposome-encapsulated drugs. Therefore, the
release of DXR was studied in the presence or absence of
IgG-PEG2000-DSPE micelles. At 60‡C, approximately 4% of
DXR was released during a 6 h incubation in the absence of
IgG-micelles and this increased only 2^3% in the presence of
IgG-micelles, when 87% of IgG was transferred to liposomes.
Although 45% of IgG-PEG2000-DSPE transferred from mi-
celles to liposomes at 37‡C over 24 h, there was less than a
4% release of DXR under these conditions.
Following the transfer of IgG-PEG2000-DSPE into pre-
formed liposomes at 60‡C, reduction of the binding activity
of IgG is possible if some denaturation of IgG occurs at this
temperature. In vitro binding studies with SIL containing
transferred anti-CD19 (SIL[anti-CD19]) were conducted with
CD19 Namalwa (human B lymphoma) cells (Fig. 4). There
was a three-fold increase in the association of SIL[anti-CD19]
to Namalwa cells compared to that of SL [no mAb], which is
similar to the fold increase previously reported for anti-CD19
coupled directly to liposomes [12]. These results show that the
transferred IgG can retain su⁄cient binding activity to
achieve selective binding of the SIL to targeted cells.
We showed in this study that IgG-PEG2000-DSPE and
mPEG2000-DSPE are transferred into the membrane of pre-
formed liposomes from IgG-micelle conjugates, with very little
DXR release during the transfer and only small increases in
liposome diameters. The resulting liposomes would be ex-
pected to have long circulation times and selective binding
to target cells in vivo. The IgG-PEG2000-DSPE transfer meth-
od described here is a simple and commercially acceptable
method to produce targeted sterically stabilized liposomal
drugs. Several liposomal preparations of anticancer drugs
are approved for clinical use or are in clinical trials, including
Caelyx/Doxil. As we envision it, the combinatorial approach
for making many di¡erent formulations of targeted liposomes
would involve a simple procedure, requiring only the selection
of a vial of ligand-PEG-micelles for a one-step incubation
with the appropriate liposomal drug formulation (Fig. 1).
Our transfer method holds out the possibility for the transfer
of a variety of antibody, peptide, and other ligands into a
variety of preformed drug-containing liposomes to create a
custom library of targeted liposomal drugs tailored to individ-
ual patient needs.
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